Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Easy BioXKRX:353810 -3.22%91 ROE % is 33.77% as of Jun. 2026, which is 21% above its 10-year median of 27.92. GuruFocus rates XKRX:353810 with a GF Score™ of 91/100 and a GF Value™ of ₩7,883.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,249 Biotechnology companies, Easy Bio ranks better than 95.52% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Easy Bio's annualized net income for the quarter that ended in Jun. 2026 was ₩40,777 Mil. Easy Bio's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was ₩120,734 Mil. Therefore, Easy Bio's annualized ROE % for the quarter that ended in Jun. 2026 was 33.77%.
The historical rank and industry rank for Easy Bio's ROE % or its related term are showing as below:
XKRX:353810'
s ROE % Range Over the Past 10 Years
Min: 19.66 Med: 27.92 Max: 37.81
Current: 37.81
During the past 6 years, Easy Bio's highest ROE % was 37.81%. The lowest was 19.66%. And the median was 27.92%.
XKRX:353810's ROE % is ranked better than 95.52% of 1249
companies
in the Biotechnology industry
Industry Median: -38.74
vs XKRX:353810: 37.81
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Easy Bio ROE % Related Terms
Easy Bio ROE % Historical Data
* Premium members only.
The historical data trend for Easy Bio's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Easy Bio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easy Bio ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Easy Bio's ROE % distribution charts can be found below:
* The bar in red indicates where Easy Bio's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Easy Bio (XKRX:353810) has a ROE % of 33.77% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Easy Bio and its competitors. This is 21% above median its historical median of 27.92. Over the past decade, Easy Bio's ROE % has ranged from 19.66 to 37.81. According to the industry distribution chart, Easy Bio ranks #56 out of 1249 companies in the Biotechnology industry, placing it in the top 4.5%.
Is Easy Bio's ROE % too high?
Easy Bio's current ROE % of 33.77% is 21% above median its 10-year median of 27.92. Over the past 10 years, this metric has ranged from a low of 19.66 to a high of 37.81. Based on the distribution chart, Easy Bio ranks #56 out of 1249 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Easy Bio has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easy Bio's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Easy Bio ranks #56 out of 1249 companies for ROE %. This places Easy Bio in the top 5% of its industry — outperforming the majority of peers. Historically, Easy Bio's own ROE % has ranged from 19.66 to 37.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Easy Bio and its competitors. Easy Bio's current ROE % is 33.77%, which is 21% above median its own 10-year median of 27.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easy Bio stock overvalued right now?
Based on GuruFocus' analysis, Easy Bio (XKRX:353810) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩7,883.07, compared to a current price of ₩6,610.00 — trading 16.1% below its estimated fair value. The current ROE % is 33.77%, which is 21% above median its 10-year median of 27.92. Easy Bio's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Easy Bio (XKRX:353810), the current ROE % is 33.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easy Bio (XKRX:353810) Overvalued in 2026?
Based on GuruFocus' analysis, Easy Bio stock appears to be undervalued.
The current stock price of ₩6,610.00 is trading 16.1% below its estimated GF Value™ of ₩7,883.07.
GuruFocus considers Easy Bio to be Modestly Undervalued.
Key valuation signals for XKRX:353810:
ROE %: 33.77% (21% above median its 10-year median of 27.92)
GF Value™: ₩7,883.07 vs. price of ₩6,610.00 (16.1% below fair value)
No single metric tells the full story. See the XKRX:353810 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:353810 has been successfully added to your 
